ICL Israel Chemicals Ltd (ICL) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of ICL Israel Chemicals Ltd stock $4.84, price $4.68, upside +3.5%, quality 50 out of 100. Rating: fairly valued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
The stock costs about what our calculation considers fair.
Low debt
Generates free cash flow
Last quarter vs. a year ago: revenue +17%, profit +52%.
Fair value $4.84 · Fairly valued
Quality 50/100
Thin margins · 4.0% net margin (TTM)
4.4% dividend yield · Watch coverage
Mixed vs. peers(7/15)
Neutral coverage
Some data
Weak Growth(revenue 3y −10.6 %/yr in USD)
Narrow moat39/100 · thin data
⟳ Cyclical
Risks from the AI analysis
🚩Price drop: Challenging fertilizer environment and overvaluation assessment🚩Dead Sea concession terms could tighten🚩Low-cost rivals like OCP or Russian producers
Watch ICL Israel Chemicals Ltd for free: we tell you when fair value or trend changes.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $3.52 – $9.59 · fair‑value band $3.04 – $5.33 · the $4.68 price screens below the $4.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow ICL Israel Chemicals in your weekly email
Every Wednesday you see whether ICL Israel Chemicals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ICL Group Ltd, together with its subsidiaries, operates as a specialty minerals and chemicals company worldwide. The company operates in four segments: Industrial Products, Potash, Phosphate Solutions, and Growing Solutions.
Show moreShow less
The Industrial Products segment produces bromine out of a solution that is a by-product of the potash production process, as well as bromine-based compounds; sells various grades of potash, salt, magnesium chloride, and magnesia products; and produces and markets phosphorous-based flame retardants and other phosphorus-based products.
The Potash segment produces and sells potash, salt, magnesium, electricity, and magnesium alloys; as well as chlorine and sylvinite.
The Phosphate segment uses phosphate commodity products to produce specialty products; sells phosphate-based fertilizers, as well as sulphuric and green phosphoric acid, and phosphate fertilizers; and offers phosphate salts and acids.
It also develops and produces functional food ingredients and phosphate additives.
The Growing Solutions segment develops, manufactures, markets, and sells fertilizers based primarily on nitrogen, potash, and phosphate, including water-soluble specialty, and controlled-release fertilizers, as well as secondary nutrients, bio-stimulants, soil conditioners, seed treatment products, and adjuvants.
It also offers digital platforms and technological solutions for farmers and agronomists.
The company serves pharmaceutical, food, oil and gas, de-icing, building and construction, oral care, paints and coatings, energy storage, water treatment, electronics, automotive, agriculture, textiles, tire manufacturing, and healthcare industries, as well as power plants and battery producers.
It sells its products through marketing companies, agents, and distributors. The company was formerly known as Israel Chemicals Ltd. and changed its name to ICL Group Ltd in May 2020. The company was incorporated in 1968 and is headquartered in Tel Aviv-Yafo, Israel.
Stock analysis
ICL Israel Chemicals Ltd (ICL) currently trades at $4.68, while our model-based Fair Value estimate is $4.84, so the stock looks roughly fairly valued today (gap 3.3%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $5.45 per share, and 8 of the 23 models we run sit above the $4.68 price.
Bear case: the Dividend Discount group reads lowest at $2.03, and 15 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $3.04 (bear) to $5.33 (bull), the price of $4.68 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
ICL Israel Chemicals Ltd reported revenue of $7.2B in FY2025 versus $7.0B in FY2021, a compound +0.7%/yr. Reported net income was $226M in FY2025, compounding −26.7%/yr from FY2021.
Key figures
Market cap $6.0B Mid · P/E ratio 19.9 · P/S ratio 0.78 · EPS (TTM) $0.2400 · Dividend yield 4.4% · Net margin 4.0% · Return on equity 5.6% · Return on assets (EBIT) 12.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at 4% fair-value upside, at 3%, ICL screens richer than that median.
Fair Value models
Bear$3.04Fair Value $4.84Bull$5.33
Price $4.68 · Upside +3.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.0283 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF$1.56$2.48$3.8179
Growth DCF$1.63$2.50$3.7078
Residual Income$3.38$3.36$3.4476
All 23 models by family
DCF Models
FCF DCF$1.56$2.48$3.8179
5Y Revenue Exit$2.74$4.86$7.6171
5Y EBITDA Exit$3.98$7.00$10.5574
5Y P/E Exit$1.12$2.06$3.0370
10Y Revenue Exit$2.11$3.85$5.9465
10Y EBITDA Exit$2.98$5.22$7.9167
10Y P/E Exit$1.28$2.05$2.8664
Earnings-Based
Graham-Dodd$1.19$2.34$2.9366
EPV$2.61$3.17$3.6574
Dividend Discount
Gordon GGM$1.48$2.03$2.5669
DDM Multi-Stage$1.48$2.02$2.6167
Multiples
P/E Multiple$2.23$2.98$3.7263
P/S Multiple$2.23$2.98$3.7258
P/B Multiple$5.86$7.81$9.7655
EV/EBIT$3.81$5.72$7.6265
EV/EBITDA$5.75$8.30$10.8567
EV/Revenue$3.05$5.17$7.2952
Asset-Based
NCAV (Graham)$1.95$2.61$3.9054
Growth DCF
Growth DCF$1.63$2.50$3.7078
Rev-Margin DCF$2.74$4.89$7.2471
Economic Profit
Residual Income$3.38$3.36$3.4476
ROIC Compounder$2.61$3.17$3.6572
Growth Earnings
Growth-Adj P/E$1.63$2.33$3.0267
The fair value above starts from this blend and is adjusted for a cyclical trough year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Start year 2020 (pandemic). Over 10 years: +2.8% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−3.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.8%
Dividend (yield on the price)4.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−13.9% vs −7.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +28.6% a year for the price and +1.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Diversified operations underpin recent earnings strength and the shift toward core minerals seeks efficiency gains, yet low returns on equity and thin margins point to a limited competitive moat.
Main risk: A competitive tender or stricter environmental and fiscal rules for the Dead Sea concession after 2030 could raise costs or limit access to low-cost potash and bromine production.
Bull case: ICL could secure favourable Dead Sea terms through its experience and expand specialty fertilizers and biostimulants to reduce reliance on commodity volumes.
Bear case: If the concession terms become significantly stricter or rivals undercut prices on core minerals, ICL might face sustained margin pressure and higher costs for its key low-cost assets.
ICL is divesting its aluminum paper chemicals and water treatment business to a Japanese buyer as part of streamlining non-core assets. Strong recent earnings reflect diversified operations yet our models currently see the stock as overvalued in a challenging fertilizer environment. Will the sharper focus on core minerals deliver sustained margins or leave the company more exposed to commodity swings?
Compare ICL Israel Chemicals Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 162 stocks
Beats the industry median on 7/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+3.5% · Above median
Profitability
Return on equity (12 months)5.6% · Below median
Return on assets1.8% · Below median
Net margin (12 months)4.0% · Below median
Operating margin (12 months)12.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)16.5% · Above median
Dividend yield (12 months)4.4% · Top 25%
Balance sheet
Debt / equity0.29× · Highest 25%
Valuation Multiplesvs Agricultural Inputs median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ICL Israel Chemicals Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ICL
Frequently asked questions
Is ICL Israel Chemicals Ltd (ICL) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $4.84 versus a price of $4.68, about +3% upside (fairly valued).
What is the fair value of ICL?
Our model-based fair value for ICL Israel Chemicals Ltd is $4.84 (as of Nov 6, 2026), built from audited fundamentals. The current price: $4.68.
What is the quality score of ICL?
ICL Israel Chemicals Ltd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ICL Israel Chemicals Ltd (ICL)?
Our model-based price target is the fair value of $4.84 (as of Nov 6, 2026) from 23 valuation models. Cautious scenario $3.04, optimistic scenario $5.33. It is a calculation from audited fundamentals, not an analyst target.
What is the ICL Israel Chemicals Ltd stock forecast for 2026?
Our models put fair value at $4.84, about +3% upside versus a price of $4.68 (fairly valued). Cautious scenario $3.04, optimistic scenario $5.33. The calculation is refreshed regularly with new filings.
What is the revenue of ICL Israel Chemicals Ltd (ICL)?
ICL Israel Chemicals Ltd reported trailing-twelve-month revenue of about $7.7B (latest available figure, as of Nov 6, 2026).
Does ICL Israel Chemicals Ltd pay a dividend?
ICL Israel Chemicals Ltd currently shows a dividend yield of 4.42% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of ICL Israel Chemicals Ltd (ICL) and when is the ex-dividend date?
ICL Israel Chemicals Ltd pays a dividend of $0.207 per share a year, a dividend yield of 4.4%. The last ex-dividend date was Sep 2, 2026. A dividend has been paid every year since at least 2005. The payout ratio is 62.1% of earnings (on adjusted earnings, reported 86.3%). Free cash flow covers the dividend 0.49 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into ICL Israel Chemicals Ltd (ICL)?
For today's price to be fair in a discounted-cash-flow model, ICL Israel Chemicals Ltd would have to grow free cash flow by +31.6 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.2 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of ICL use?
Our models discount ICL Israel Chemicals Ltd at 9.9 %: a base by market capitalisation (mid), damped by beta 1.05, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ICL Israel Chemicals Ltd that is +31.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has ICL Israel Chemicals Ltd (ICL) delivered so far?
Over the past 5 years revenue at ICL Israel Chemicals Ltd grew +7.2 % a year. The price currently implies free-cash-flow growth of +31.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ICL Israel Chemicals Ltd (ICL) growing?
The median revenue growth in the sector is +9.8 % a year. That is the yardstick for the growth priced into ICL Israel Chemicals Ltd (+31.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ICL Israel Chemicals Ltd (ICL)?
The free-cash-flow yield on the price is 2.15 %: that much free cash flow ICL Israel Chemicals Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ICL Israel Chemicals Ltd (ICL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ICL Israel Chemicals Ltd it is $4.84 per share (as of Nov 6, 2026), against a price of $4.68. It is the blended result of 23 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is ICL Israel Chemicals Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ICL trades below its calculated fair value: price $4.68, fair value $4.84, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ICL?
No. The price is what the market pays today ($4.68); the fair value is what the company's own numbers justify ($4.84). For ICL Israel Chemicals Ltd the two are $0.1617 per share apart. That gap is exactly why we show both numbers side by side.
How much is ICL Israel Chemicals Ltd worth?
The market values ICL Israel Chemicals Ltd at about $6.0B (market capitalisation, as of Nov 6, 2026). Per share that is $4.68; our models calculate a fair value of $4.84 per share.
What do the bullish and bearish scenarios say about ICL?
Our models span a range for ICL Israel Chemicals Ltd: cautious scenario $3.04, base $4.84, optimistic $5.33 per share (as of Nov 6, 2026, price $4.68). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ICL?
ICL Israel Chemicals Ltd trades at a price-to-earnings ratio of 19.9 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.84 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 18.7 (reported for FY2025: 26.0). Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings, 6 of the years ex one-offs: 13.7. Other multiples: PEG 9.4, P/B 1.0, P/S 0.8, EV/EBITDA 5.4.
What is the PEG ratio of ICL?
The PEG ratio of ICL Israel Chemicals Ltd is 9.44 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of ICL Israel Chemicals Ltd (ICL)?
Balance-sheet figures for ICL Israel Chemicals Ltd (as of Nov 6, 2026): return on equity 5.6%, debt of 0.29 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is ICL from its 52-week high?
ICL Israel Chemicals Ltd trades at $4.68, about 30% below its 52-week high of $6.70 and 7% above the low of $4.36 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $4.84 is for.
Which stocks are comparable to ICL Israel Chemicals Ltd?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ICL Israel Chemicals Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price $4.68, calculated fair value $4.84 (+3%), Quality Score 50/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ICL calculated?
We run ICL Israel Chemicals Ltd through 23 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $4.84 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. ICL Israel Chemicals Ltd currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ICL Israel Chemicals Ltd (ICL)?
The closing price on Nov 6, 2026 was $4.68. Our model-based fair value is $4.84, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ICL Israel Chemicals Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of ICL Israel Chemicals Ltd (ICL) come from?
Earnings per share at ICL Israel Chemicals Ltd grew −1.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +2.2 %, EBIT margin −0.9 %, tax rate −1.1 %, residual (interest, one-offs) −1.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of ICL Israel Chemicals Ltd
How large is the market capitalisation of ICL Israel Chemicals Ltd (ICL)?
The market capitalisation of ICL Israel Chemicals Ltd is $6.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ICL Israel Chemicals Ltd (ICL)?
The price-to-sales ratio of ICL Israel Chemicals Ltd is 0.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ICL Israel Chemicals Ltd (ICL)?
Earnings per share at ICL Israel Chemicals Ltd are $0.2400 (price ÷ EPS = P/E 19.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ICL Israel Chemicals Ltd (ICL)?
The dividend yield of ICL Israel Chemicals Ltd is 4.4% (payout 62.1%, on adjusted earnings, reported 86.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ICL Israel Chemicals Ltd (ICL)?
The net margin of ICL Israel Chemicals Ltd is 4.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ICL Israel Chemicals Ltd (ICL)?
The return on equity (ROE) of ICL Israel Chemicals Ltd is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ICL Israel Chemicals Ltd (ICL)?
On an EBIT basis the return on assets of ICL Israel Chemicals Ltd is 12.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ICL Israel Chemicals Ltd (ICL)?
The operating margin of ICL Israel Chemicals Ltd is 12.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ICL Israel Chemicals Ltd (ICL)?
Revenue at ICL Israel Chemicals Ltd is growing +16.5% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ICL Israel Chemicals Ltd (ICL)?
Earnings per share at ICL Israel Chemicals Ltd are growing +51.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does ICL Israel Chemicals Ltd (ICL) carry?
The net debt of ICL Israel Chemicals Ltd is $2.5B (fiscal year 2025, ≈ 19.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ICL Israel Chemicals Ltd in the live analysis
One click puts ICL Israel Chemicals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026